Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Belzutifan
Related studies linked through entity extraction aliases.
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Status
- RECRUITING
- Phase
- PHASE3
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Status
- RECRUITING
- Phase
- PHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
- Status
- RECRUITING
- Phase
- PHASE3
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
- Status
- RECRUITING
- Phase
- PHASE2
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
- Status
- RECRUITING
- Phase
- PHASE1
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)
- Status
- COMPLETED
- Phase
- PHASE1
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
- Status
- COMPLETED
- Phase
- PHASE1
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
- Status
- RECRUITING
- Phase
- PHASE2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Status
- RECRUITING
- Phase
- PHASE2
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)
- Status
- COMPLETED
- Phase
- PHASE1